{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihrq65uthbv4ezm2hk4nksfypcsopl57s2capu2x6zdrtx5dpbos4",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mlkyff7eb262"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigyynm3qvwsptjfdvfeswfnuw6ipk6nxnzqa44nuyt6cqvyjswwvu"
    },
    "mimeType": "image/jpeg",
    "size": 75423
  },
  "path": "/2026/05/11/medicare-spending-less-than-expected-alzheimers-drugs-leqembi-kisunla/?utm_campaign=rss",
  "publishedAt": "2026-05-11T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Exclusive",
    "Insurance",
    "Pharma",
    "Politics",
    "Biogen",
    "biotechnology",
    "CMS",
    "drug development",
    "Drug prices",
    "Eli Lilly",
    "Pharmaceuticals",
    "Policy",
    "public health",
    "STAT+"
  ],
  "textContent": "Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.",
  "title": "STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs",
  "updatedAt": "2026-05-09T16:51:20.000Z"
}